Company intelligence / Profile preview
OTR Therapeutics
Shanghai, Shanghai, Chinaotr-tx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
OTR Therapeutics is a newly founded private biotech (March 2025) focused on acquiring and discovering preclinical and early-clinical assets in oncology, immunology and inflammation, cardiometabolic and neurological diseases; as of the latest disclosures, all programs are at preclinical or early clinical stages with no publicly reported clinical trial data yet.[3][2]
- Therapeutic areas
- OncologyCardiovascularImmunologyNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Bayer Co.Lab life sciences incubator network
Beyond the preview
Go deeper on OTR Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTR Therapeutics.